drugset / Trial / NCT02017236

A Food Effect Phase I Study of the Volitinib in Healthy Subjects

NCT02017236

Phase 1 Completed 25 enrolled Hutchison Medipharma Limited
RandomizedCrossoverOpen-labelHealth-services research

Summary

The purpose of this study is to evaluate to determine the effect of food on the PK of a single dose of 600 mg Volitinib and its two major metabolites in healthy subjects.

Timeline

Start
2013-11
Primary completion
2014-03
Completion
2014-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Savolitinib Small molecule 600 mg Oral

Indications

No indication recorded.